1 / 21

Eisai Inc.

Mission, Vision, Values. Human Health Care (HHC) missionAlso Florence Nightingale's signature Innovative solutions for preventive careCure and care for health and well being worldwideVision: responsible, focused, efficient, innovative and solution-oriented pharma company.Values: Integrity, respect, professionalism, quality,and teamwork. .

liam
Download Presentation

Eisai Inc.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Eisai Inc. Ramzi Ayyad Nita Silimkhan Sean Ryan

    2. Mission, Vision, Values Human Health Care (HHC) mission Also Florence Nightingale's signature Innovative solutions for preventive care Cure and care for health and well being worldwide Vision: responsible, focused, efficient, innovative and solution-oriented pharma company. Values: Integrity, respect, professionalism, quality, and teamwork.

    3. Eisai Corporation: A Global Company Founded as Nihon Eisai Co. in Japan in 1941. Current headquarters in Tokyo Japan More than 9,000 employees worldwide 40 subsidiaries and 2 Joint Ventures worldwide. Joint Ventures: Bracco Corporation (Italian Company), P.T. Indonesia. Wholly Owned Subsidiaries present in 19 countries: North America : U.S.A (5 sites) Europe: U.K., Sweden, Germany, France, Italy, Switzerland, Spain, Netherlands Asia: Japan, Indonesia, Taiwan, China, India, Malaysia, Singapore, Philippines, South Korea, Thailand

    4. Eisai Inc. of North America Eisai first established in the U.S. in 1981 Headquarters in Woodcliff Lake, NJ as of 2007 Chairman and CEO : Hajime Shimizu  President and COO : Lonnel Coats  VP Business Development: Alex Scott  VP Finance and CFO: Kenneth R (Ken) Klauser  VP and General Counsel: Douglas B. Snyder  VP Sales and Marketing: Frank Ciriello  Research Facilities: Eisai Medical Research Inc., Ridgefield NJ Eisai Research Institute of Boston, Andover, Ma Eisai Inc./ RTP, Research Triangle Park, NC Other: Eisai Machinery : Pharmaceutical Machinery Sales Eisai Medical Research: Site specifically deals with clinical research and drug development Eisai Research Institute of Boston: process and research Eisai RTP: pharmaceutical production and formulation R&D facility Eisai Medical Research: Site specifically deals with clinical research and drug development Eisai Research Institute of Boston: process and research Eisai RTP: pharmaceutical production and formulation R&D facility

    5. Eisai’s Alliance/Acquisitions History in the U.S. 1994 -- agreement with Pfizer Inc to co-promote Aricept® 1997 -- agreement with Janssen Pharmaceuticals Inc. to co-promote Aciphex® 2002 -- acquires Cerebyx from Warner Lambert company. 2003 -- agreement with Teva Pharmaceuticals to co-promote rasagiline. 2004 -- acquires anti-epileptic drug Zonegran® from Elan Corporation 2006 -- acquires four oncology-related products from Ligand Pharmaceuticals. 2007 –- acquires Morphotek biopharmaceutical company Morphotek, a biopharmaceutical company that discovers and develops monoclonal antibodies for oncology, inflammatory, and infectious diseases. Morphotek, a biopharmaceutical company that discovers and develops monoclonal antibodies for oncology, inflammatory, and infectious diseases.

    6. Eisai Inc.: Inside the numbers

    7. Financial Highlight Comparison

    8. Percent Growth Rate

    9. Liquidity Ratio Comparisons

    10. Profitability Ratios

    11. Eisai Recent News Development of Parkinson disease drug, Perampanel (E 2007), was halted after failing late-stage drug trial. (Bloomberg.com) Eisai won a court battle barring Teva pharmaceutical from selling the Alzheimer drug, Aricept, which accounts for 40% of the company’s revenues . (Bloomberg.com) Eisia to resume clinical trial studies on E2012, an alzheimer drug. (pharmalive.com). FDA approved Aloxi injection for post operative nausea and vomiting (Eisai press release, 3/02/08) Aricept patent has three years before expiration.Aricept patent has three years before expiration.

    12. Eisai’s Pharmaceuticals Two major moneymakers Aricept Aciphex Three others Cerebryx Zonegran Fragmin

    13. Aricept improves cognition for Alzheimer’s disease - oral Sales from 75 countries (but not England) Best pill on the market, but far from a miracle pill Off-patent: November 2010

    14. Aciphex Proton pump inhibitor, for GERD (gastroesophageal reflux disease) - oral Co-marketed with PriCara (Ortho-McNeil, part of J&J) in U.S.; marketed as Pariet outside U.S. Also approved for treatment of ulcers w/antibiotics (2002) Off-patent: May 2013

    15. Fragmin Clot-buster - injectable Bought U.S. rights from Pfizer Stops deep-vein thrombosis (DVT) which can lead to pulmonary edema (PE) Also approved for angina w/aspirin Low-molecular-weight heparins – general heparin problems with Chinese suppliers

    16. Eisai’s Seizure Portfolio Cerebyx – seizure control - injectable -Owned by Pfizer, marketed by Eisai via hospital-based sales force Zonegran – seizure medication - oral -Bought from Elan

    17. Eisai’s Oncology Portfolio ONTAK Targretin (capsules) Targretin (gel) Panretin (gel)

    18. Eisai’s Research Focus Neurology Gastrointestinal disorders Cancer Acute Care

    19. The Eisai Research Pipeline Phase I Compounds E5555 – Critical care acute coronary syndrome Aciphex – Gastrointestinal disorder extended release formulation E7080 – Cancer oral anti-cancer agent E7974 – Cancer E7820 - Cancer

    20. The Eisai Research Pipeline Phase II Compounds AS-3201 – Diabetic Neuropathy E7389 – Cancer non small cell lung cancer E2007 – Neurology-migraine prevention Aciphex – Gastrointestinal disorder, pediatric use Aciphex - Gastrointestinal disorder, intermittent therapy for symptomatic gastroesophageal reflux disease

    21. The Eisai Research Pipeline Phase II Compounds (cont.) E7389 – Breast cancer E2007 – Neurology-epilepsy E7389 – Prostate cancer

    22. The Eisai Research Pipeline Phase III/Submission to FDA E5564 – Critical care-severe sepsis Rufinamide – epilepsy Aricept – Severe Alzheimer’s disease

More Related